Previous 10 | Next 10 |
Gainers: Cohen & Company (COHN) +25%. Pintec Technology Holdings (PT) +17%. Altimeter Growth (AGCUU) +9%. Altimeter Growth (AGC) +8%. U.S. Global Investors (GROW) +7%.Losers: The GEO Group (GEO) -20%. Big Rock Partners Acquisition (BRPA) -12%. Hywin Holdings (HYW) -12%. Upstart Holdings (...
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir PR Newswire RADNOR, Pa. , April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be...
Gainers: X Financial (XYF) +15%. Marathon Digital Holdings (MARA) +11%. 360 DigiTech (QFIN) +10%. FinVolution Group (FINV) +10%. ARYA Sciences Acquisition (ARYA) +9%.Losers: Big Rock Partners Acquisition (BRPA) -10%. Stable Road Acquisition (SRAC) -9%. Holicity (HOL) -9%. Atlantic American (A...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to the stock market today! The Ever Given is free , Wall Street is caught up in a fire sale tizzy and cryptos are climbing again. So what will the stock market do today? And what do you need to kno...
Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with broadband service provider.F...
/C O R R E C T I O N -- NeuroRx/ PR Newswire In the news release, NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b /3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19, issued ...
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 PR Newswire RADNOR, Pa. , March 29, 2021 /PRNewswire/ -- NeuroRx, I...
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure Results to be Presented at Investor Call on Monday, March 29th at 8:30am EDT PR Newswire RADNOR, Pa. , March 26, 2021...
WILMINGTON, DE and DELRAY BEACH, FL / ACCESSWIRE / March 15, 2021 / NeuroRx, Inc. ("NeuroRx"), a clinical stage-small molecule pharmaceutical company and Big Rock Partners Acquisition Corp. ("Big Rock") (NASDAQ:BRPA), a special purpose acquisition company, are pleased to announce that inst...
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration Feasibility work underway to determine the compatibility of NeuroRx's ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF's Thin-Film Freezing technology Dry powder ...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc Com Company Name:
BRPA Stock Symbol:
NASDAQ Market:
NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA) - Newly formed publicly traded company NRx Pharmaceuticals, Inc. (NRx) to be traded under the ticker symbol "NRXP" on the Na...
Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (Nasdaq:BRPA), a publicly traded special purpose acquisition company, today confirmed that its ...
NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia PR Newswire RADNOR, Pa. and TBLISI, Georgia , April 28, 2021 /PRNewswire/ -- NeuroRx today announ...